Daraxonrasib

Buy Daraxonrasib (Rasonque) Tablets in Indi
Generic Name/API:Daraxonrasib
Packaging:Store at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C and 30°C (59°F and 86°F).
Storage:Store at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C and 30°C (59°F and 86°F).
Dosage:300 mg orally once daily until disease progression or unacceptable toxicity.
Strength:Daraxonrasib is available as tablets of 100 mg and 150 mg.
Indication:Daraxonrasib is approved for adults with metastatic pancreatic adenocarcinoma (mPDAC) who have received at least one prior systemic therapy or are not candidates for multiagent therapy.

Daraxonrasib (Rasonque), is an anti-cancer medication used for the treatment of the most common form of pancreatic cancer. It is an orally bioavailable RAS(ON) multi-selective tri-complex inhibitor of the oncogenic mutant and wild-type variants of KRAS, HRAS and NRAS.

Approved by the U.S. FDA on August 26, 2026, for adults with metastatic pancreatic adenocarcinoma (mPDAC) who have received at least one prior systemic therapy or are not candidates for multiagent therapy.

Strength:

Daraxonrasib is available as tablets of 100 mg and 150 mg.

Dosage: 

300 mg orally once daily until disease progression or unacceptable toxicity.

Adverse Reactions:

Most common adverse reactions (≥ 20%) are rash, diarrhea, stomatitis, nausea, fatigue, vomiting, abdominal pain, edema, decreased appetite, and hemorrhage.

Storage: 

Store at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C and 30°C (59°F and 86°F).

  • Dermatologic and Soft Tissue Toxicity

Daraxonrasib can cause dermatologic toxicity, which may be severe. Clinical manifestations included, but were not limited to, rash, pruritus, paronychia, dry skin, and skin fissures.

  • Stomatitis and Oral Disorders

Daraxonrasib can cause stomatitis, including mouth ulcers and oral mucositis.

  • Diarrhea

Daraxonrasib can cause diarrhea. If diarrhea occurs, administer antidiarrheal treatment as clinically indicated.

  • Gastrointestinal Perforation

Daraxonrasib can cause gastrointestinal perforation. Withhold Daraxonrasib if gastrointestinal perforation is suspected. Reduce the dose or permanently discontinue Daraxonrasib if no other potential causes of gastrointestinal perforation are identified.

  • Interstitial Lung Disease (ILD)/Pneumonitis

Daraxonrasib can cause interstitial lung disease or pneumonitis. Monitor patients for new or worsening pulmonary symptoms. Withhold Daraxonrasib if ILD/pneumonitis is suspected. Reduce the dose or permanently discontinue Daraxonrasib if no other potential causes of ILD/pneumonitis are identified.

  • Embryo-Fetal Toxicity

Advise females of reproductive potential to use effective contraception during treatment with Daraxonrasib and for 1 week after the last dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with Daraxonrasib and for 1 week after the last dose.

Process to Import Medicine

FAQ

Daraxonrasib (Rasonque) is a prescription oncology medicine approved by the US FDA for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy. Treatment suitability should be assessed by an oncologist according to the applicable prescribing information.

The availability of Daraxonrasib (Rasonque) Tablets in India depends on its current Indian regulatory status and applicable access requirements. Contact 24/7QualityMeds to enquire about sourcing feasibility, subject to product verification and the relevant import regulations.

Daraxonrasib (Rasonque) is administered orally according to the applicable prescribing information. The US-approved label specifies a recommended dosage of 300 mg once daily, with tablets swallowed whole. The treating oncologist must determine the appropriate treatment and any dose adjustments.

Common adverse reactions reported in the US prescribing information include rash, diarrhoea, stomatitis, nausea, fatigue, vomiting, abdominal pain, swelling, decreased appetite, and haemorrhage. Serious risks include gastrointestinal perforation and lung inflammation. Patients should consult their oncologist about the full safety information and required monitoring.

Documentation requirements depend on the product’s regulatory status and the applicable access pathway. A valid prescription, relevant medical documentation, and supporting import documents may be required. Confirm the specific requirements with the treating physician and medicine access provider.

Yes, Rasonque (daraxonrasib) is an oral tablet medicine. The US-approved product information lists 100 mg and 150 mg tablet strengths. Confirm the specific product, packaging, and availability for India before proceeding with a sourcing enquiry.

The price of Daraxonrasib (Rasonque) Tabelts in India depends on verified product details, sourcing arrangements, and applicable import-related costs. Contact 24/7QualityMeds for a current, product-specific quotation, subject to availability and regulatory requirements.

To enquire about Daraxonrasib (Rasonque) in India, consult the treating oncologist and submit a medicine sourcing enquiry to 24/7QualityMeds. The team can assess sourcing feasibility and explain the applicable prescription, documentation, and regulatory requirements before any supply arrangement proceeds.

You can contact 24/7QualityMeds to enquire about Daraxonrasib (Rasonque) sourcing options in India. The team can review the product details and explain the next steps, subject to availability, medical documentation, and applicable regulatory requirements.

To enquire about buying Daraxonrasib (Rasonque) in Delhi, contact 24/7QualityMeds to check product availability, pricing, and sourcing options. Supply is subject to product verification, applicable prescription requirements, and Indian import regulations.

Related products